Memorial Sloan Kettering Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Memorial Sloan Kettering Cancer Center sits in the top decile of US sponsors by registered trial count (#6 of 15,751 sponsors by registered trial count).
Memorial Sloan Kettering Cancer Center: 1,884 sponsored US clinical trials, 327 recruiting.
Memorial Sloan Kettering Cancer Center sponsors 1,884 registered US clinical trials on ClinicalTrials.gov, 327 of them currently recruiting, and 1,104 completed. 75 of these trials are in Phase 3-4 (later-stage) and 1,101 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 98 trials.
Top-decile sponsor footprint
Memorial Sloan Kettering Cancer Center ranks in the top decile of sponsors by registered trial count (#6 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
1,884 total, page 37 of 38
Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer
NCT00003539
Decitabine in Treating Patients With Myelodysplastic Syndrome
NCT00003361
T138067 Sodium in Treating Patients With Advanced Refractory Cancer
NCT00003359
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
NCT00003427
Identification of New Colorectal Cancer Genes
NCT00582335
Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors
NCT00003242
Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT00003358
Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease
NCT00003357
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
NCT00003341
Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer
NCT00003342
Green Tea Extract in Treating Patients With Advanced Solid Tumors
NCT00003197
Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21
NCT00698711
Ifosfamide and Topotecan in Treating Patients With Refractory Solid Tumors
NCT00003198
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma
NCT00003346
Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT00003345
Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer
NCT00003105
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
NCT00003173
Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer
NCT00003133
Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma
NCT00003101
Combination Chemotherapy, Radiation Therapy and Surgery in Treating Patients With Cancer of the Esophagus
NCT00003087
Chemotherapy in Treating Patients With Solid Tumors
NCT00003103
Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors
NCT00003004
Cisplatin and Irinotecan in Treating Patients With Locally Advanced or Metastatic Esophageal or Gastric Cancer
NCT00003055
Computer Planned Radiation Therapy in Treating Patients With Prostate Cancer
NCT00003104
AIDS and Cancer Specimen Bank (ACSB)
NCT00587912
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
NCT00003022
Combination Chemotherapy as Induction Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
NCT00003037
Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer
NCT00590109
Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer
NCT00003025
Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer
NCT00003023
PET Scans in Patients With Locally Advanced Breast Cancer
NCT00109785
Differential Risks for Melanoma: p16 and DNA Repair
NCT00615095
Spectroscopy With Surface Coils and Decoupling
NCT00581815
Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian Cancer
NCT00002928
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma
NCT00002982
PET Scan in Treating Patients With Metastatic Prostate Cancer
NCT00002981
PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery
NCT00002930
Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer
NCT00002919
Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
NCT00002890
Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
NCT00002800
Combination Chemotherapy Before and After Surgery in Treating Patients With Stomach Cancer
NCT00002783
Combination Chemotherapy and Radiation Therapy in Treating Patients With Colorectal Cancer
NCT00002801
A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)
NCT00592111
Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma
NCT00002766
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia, Osteosarcoma, or Non-Hodgkin's Lymphoma
NCT00002738
T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia
NCT00002718
Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus
NCT00002711
Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma
NCT00002697
Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma
NCT00002691
Prevalence+Significance of Paraneoplastic Autoantibodies in Many Cancers
NCT00608452
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 461 |
| Phase 2 | 640 |
| Phase 3 | 67 |
| Phase 4 | 8 |
Therapeutic Areas
What is open in the Memorial Sloan Kettering Cancer Center pipeline
327 recruiting of 1,884 indexed (17% open); 1,104 completed (59%).
Phase mix: 75 late (III/IV) vs 1,101 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (98 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.